CD4 (CD4 Molecule)

P1, N=32, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Nov 2025 --> Jun 2026

In summary, this study illustrates that neoplastic T cells can show an NK-like immunophenotype. Features useful for supporting T-lineage in this context include cytoplasmic CD3 expression assessed using a T-cell-specific CD3 antibody, clonal TCR gene rearrangement, BCL11B expression, and detection of TCRαβ, TCRγδ, or TRBC by immunohistochemistry.

CD8+ cytotoxic T lymphocytes and CD4+ helper T lymphocytes were promoted by HZ-1 both in spleens and tumors. To sum up, the interaction of HZ analogs with multiple G4s formulates a new concept for anticancer strategies.

Our study depicts the landscape of neutrophils in GP skin and highlights HLA-DR+ neutrophils with possible role in disease pathogenesis.

These alterations, together with oxidative stress, promote a pro-tumorigenic microenvironment. A deeper understanding of these mechanisms may enable early biomarker identification and the design of targeted preventive and therapeutic strategies for lung cancer in PLWH.

Patients with liver metastases exhibited T cell senescence and metabolic hyperactivation, correlating with therapeutic resistance. These findings highlight that pre-existing tumor immunogenicity and T cell functional capacity are associated with response to RIN therapy, and that RIN treatment may facilitate both systemic T cell activation and local TME modulation.

P2, N=33, Not yet recruiting, Jennifer Dorth

In a bilateral tumor model, IROTD NPs effectively inhibit both primary and distant tumor growth. Overall, this work presents a rationally designed combinatorial nanoplatform that effectively ignites systemic immune response, thus establish a prospective chemo-immunotherapeutic stratagem for cancer treatment.

These findings expanded treatment options and supported personalized decisions. R/M HNSCC, Immunotherapy, Real-world study, Efficacy and survival differences, Predictive markers.

N184 induces differentiation of IL-9-producing CD8+ T cells in vitro and elicits antitumour immunity in an IL-9-dependent manner.

P=N/A, N=100, Recruiting, University of Liverpool | Trial completion date: Dec 2028 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027

P1, N=47, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2026 --> Oct 2026